The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases
Open Access
- 13 July 2020
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 22 (11), 1915-1916
- https://doi.org/10.1038/s41436-020-0878-2
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoringGenetics in Medicine, 2019
- Research priorities for liver glycogen storage disease: An international priority setting partnership with the James Lind AllianceJournal of Inherited Metabolic Disease, 2019
- Inborn Errors of Metabolism with HypoglycemiaPediatric Clinics of North America, 2018
- Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcomeJournal of Inherited Metabolic Disease, 2016
- Rapid Ultraperformance Liquid Chromatography–Tandem Mass Spectrometry Assay for a Characteristic Glycogen-Derived Tetrasaccharide in Pompe Disease and Other Glycogen Storage DiseasesClinical Chemistry, 2012
- Assessing disease severity in Pompe disease: The roles of a urinary glucose tetrasaccharide biomarker and imaging techniquesAmerican Journal Of Medical Genetics Part C-Seminars In Medical Genetics, 2012
- Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarkerGenetics in Medicine, 2009
- Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogenClinica Chimica Acta; International Journal of Clinical Chemistry, 1988
- Increased urinary excretion of a glucose‐containing tetrasaccharide in patients with duchenne muscular dystrophyFEBS Letters, 1979